Elderly Falls Prevention With sLiFE Program in Primary Care

Effectiveness of the sLiFE Program to Reduce Falls and Frailty in Elderly People in Primary Care. Randomized Clinical Trial

This study aims to guide older people living in the community on appropriate strategies within a fall prevention program. This program is aimed at training in daily activities carried out through group workshops (guided by a physiotherapist) and at preventing risk situations at home.

Study Overview

Detailed Description

Two-arm, non-blind, non-inferiority experimental design. Multicenter, randomized trial.

The study tries to assess whether a group intervention following the principles of the sLiFE program is more effective than an usual health advice reducing the incidence of falls.

Study Type

Interventional

Enrollment (Estimated)

650

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Emiliano Rodríguez-Sánchez, Dr
  • Phone Number: 923231859
  • Email: emiliano@usal.es

Study Contact Backup

Study Locations

      • Salamanca, Spain, 37005
        • Recruiting
        • Primary Care Research Unit of Salamanca (APISAL)
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • People older than 65 years of age
  • Living at home
  • Speak and read Spanish

Exclusion Criteria:

  • Heart failure (NYHA class III and IV)
  • Recent stroke (<6 months)
  • Parkinson's disease
  • In active cancer treatment (last 6 months)
  • GOLD class III and IV chronic obstructive pulmonary disease
  • Unstable lower extremity fracture
  • Amputated lower extremity
  • Treatment less than 6 months of depression
  • Uncontrolled resting blood pressure of a systolic > 160 or diastolic > 100 or more
  • Unavailability for intervention, planned travel or relocation more than 2 months within the first 6 months of the study
  • Moderate to severe cognitive impairment (Mini Mental cognitive assessment <23)
  • Current participation in another interventional clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group
The strength and balance activities of the sLiFE program will be carried out. Participants will be invited to participate in groups of about 14 people in Primary Care Heath Centers.
Subjects will participate in groups of about 14 to implement the program.
Placebo Comparator: Control Group
Participants will receive the usual health advice.
Subjects will receive the usual care advice

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health effects
Time Frame: 6 months
It will be measured using the quality of life questionnaire EQ-5D
6 months
Incidence of falls
Time Frame: 6 months
Number of falls in relation to the degree of physical activity.
6 months
Physical activity
Time Frame: 8 days
It will be evaluated with a digital pedometer for 9 consecutive days
8 days
Physical activity
Time Frame: 6 months
It will be evaluated with the Global Physical Activity Questionnaire
6 months
Frailty
Time Frame: 6 months
Frailty will be measured according to the five criteria of Fried's phenotype: 1) Low muscle strength; 2) Poor nutrition; 3) Poor endurance; 4) Slow walking and 5) Low physical activity.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fear of falling
Time Frame: 6 months
It will be assesses using the Short Falls International Scale of Efficacy (Short FES I). It measures of "concerns about falling". This scale has 7 items with a Likert scale with 4 options: 1) not at all concerned, 2) somewhat concerned, 3) fairly concerned, and 4) very concerned.
6 months
Cognitive assessment
Time Frame: 6 months
It will be evaluated with the Montreal Cognitive Assessment (MoCA): 30 questions and takes 10-12 minutes to complete.
6 months
Motor function
Time Frame: 6 months
It will be evaluated with the Short Physical Performance Battery (SPPB). It assesses three aspects of mobility: balance, gait speed and strength of limbs or lower limbs to get up from a chair
6 months
Adherence to exercise
Time Frame: 6 months
It will be assessed using the Exercise Adherence Rating Scale (EARS). It is composed of 16 items scored using a 5-point Likert scale (0 = completely agree to 4 = completely disagree) with a possible summed score range from 0 to 64.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Luis García-Ortiz, Dr, Primary Health Care Research Unit

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2023

Primary Completion (Estimated)

July 1, 2024

Study Completion (Estimated)

July 31, 2025

Study Registration Dates

First Submitted

June 11, 2023

First Submitted That Met QC Criteria

June 11, 2023

First Posted (Actual)

June 22, 2023

Study Record Updates

Last Update Posted (Actual)

October 18, 2023

Last Update Submitted That Met QC Criteria

October 16, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GRS 2502/B/22

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frailty

Clinical Trials on Intervention Group

Subscribe